Research programme: proto oncogene protein c-myc inhibitors - Sorrento Therapeutics

Drug Profile

Research programme: proto oncogene protein c-myc inhibitors - Sorrento Therapeutics

Latest Information Update: 22 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Scripps Research Institute
  • Developer Sorrento Therapeutics; The Scripps Research Institute
  • Class Small molecules
  • Mechanism of Action Proto oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Aug 2014 Preclinical trials in Cancer in USA (unspecified route) prior to August 2014
  • 21 Jul 2014 Sorrento Therapeutics receives Small Business Technology Transfer Research (STTR) grant from the National Cancer Institute (USA) for development of the proto oncogene protein c-myc inhibitors in Cancer
  • 21 Jul 2014 Early research in Cancer in USA (unspecified route) prior to July 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top